{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:42:40Z","timestamp":1789684960439,"version":"4.0.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clindermatol.2019.07.023","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T19:46:29Z","timestamp":1564170389000},"page":"384-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps"],"prefix":"10.1016","volume":"38","author":[{"given":"Renee M.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysha","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Motaparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2019.07.023_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","article-title":"First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up","volume":"34","author":"Ahmed","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3389\/fimmu.2018.00810","article-title":"Ultra-low dosage regimen of rituximab in autoimmune blistering skin conditions","volume":"9","author":"Alaibac","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0020","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0025","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0035","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","article-title":"Rituximab as first-line treatment of pemphigus","volume":"389","author":"Schmidt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12671","article-title":"Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab","volume":"31","author":"Balighi","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0050","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and -potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamadermatol.2018.5954","article-title":"Prevalence estimates for pemphigus in the United States: a sex- and age-adjusted population analysis","volume":"155","author":"Wertenteil","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0070","first-page":"72","article-title":"Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis","volume":"99","author":"Kridin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0075","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2018.00238","article-title":"Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature","volume":"5","author":"Bech","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0090","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0095","doi-asserted-by":"crossref","unstructured":"Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010:CD002292.","DOI":"10.1002\/14651858.CD002292.pub3"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0105","doi-asserted-by":"crossref","unstructured":"Ahmed AR, Shetty S, Kaveri S, et al. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74:700-708.e703.","DOI":"10.1016\/j.jaad.2015.11.030"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0125","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000452828","article-title":"Successful treatment of a bullous pemphigoid patient with rituximab who was refractory to corticosteroid and omalizumab treatments","volume":"9","author":"Bilgi\u00e7 Temel","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjd.13307","article-title":"Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients","volume":"172","author":"Tomsitz","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2015.11.006","article-title":"Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab","volume":"2","author":"Batts","year":"2016","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0155","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ced.13092","article-title":"Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin","volume":"42","author":"Nguyen","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","article-title":"Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jaad.2016.01.020","article-title":"Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP)","volume":"74","author":"Maley","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0180","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1001\/jamadermatol.2016.3434","article-title":"Rituximab for the treatment of isolated refractory desquamative gingivitis due to mucous membrane pemphigoid","volume":"152","author":"Haefliger","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0195","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/ICO.0000000000001024","article-title":"Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis\u2014an interventional case series","volume":"35","author":"Steger","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0200","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00417-017-3603-3","article-title":"Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study","volume":"255","author":"You","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0205","doi-asserted-by":"crossref","DOI":"10.5070\/D32110028946","article-title":"IgM ocular cicatricial pemphigoid: a unique insight into the immune system","volume":"21","author":"Tazudeen","year":"2015","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0210","first-page":"45","article-title":"Monoclonal anti-CD20 antibody therapy in cicatrical pemphigoid with oral and hypopharyngeal involvement and related conditions","volume":"6","author":"Wollina","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jdcr.2018.11.004","article-title":"Linear IgA bullous dermatosis treated with rituximab","volume":"5","author":"Pinard","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0220","doi-asserted-by":"crossref","unstructured":"Kaya \u0130slamo\u011flu ZG, Aky\u00fcrek FT. A case of recalcitrant linear IgA bullous dermatosis: successfully treated with rituximab. Dermatol Ther. 2019:e12911.","DOI":"10.1111\/dth.12911"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0225","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clindermatol.2016.02.010","article-title":"Pemphigoid gestationis: toward a better understanding of the etiopathogenesis","volume":"34","author":"Sadik","year":"2016","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0230","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2133.2007.07982.x","article-title":"Severe persistent pemphigoid gestationis: long-term remission with rituximab","volume":"157","author":"Cianchini","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0235","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1111\/jdv.13962","article-title":"Pemphigoid gestationis: a successful preventive treatment by rituximab","volume":"31","author":"Tourte","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0240","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald","year":"2015","journal-title":"J Dtsch Dermatol Ges."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0245","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0250","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/jdv.14119","article-title":"Pregnancy outcome after rituximab treatment before conception in patients affected by severe pemphigus vulgaris\/superficialis","volume":"31","author":"Vassallo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0255","doi-asserted-by":"crossref","unstructured":"Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford). 2008;47(suppl 3):iii28-31.","DOI":"10.1093\/rheumatology\/ken168"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0260","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0265","doi-asserted-by":"crossref","unstructured":"Bragnes Y, Boshuizen R, de Vries A, et al. Low level of rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford). 2017;56:1047-1048.","DOI":"10.1093\/rheumatology\/kex039"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000106585","article-title":"Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab","volume":"215","author":"Wallet-Faber","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0275","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2006.07596.x","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0280","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archderm.142.2.147","article-title":"Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab","volume":"142","author":"Schmidt","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/pde.12006","article-title":"A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy","volume":"31","author":"McKinley","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0295","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12726","article-title":"The use of rituximab in treatment of epidermolysis bullosa acquisita: three new cases and a review of the literature","volume":"31","author":"Bevans","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0300","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40257-014-0098-0","article-title":"Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment","volume":"15","author":"Contestable","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0305","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.38051","article-title":"Oral mucosal involvement in bullous lupus","volume":"65","author":"Anyanwu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0310","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RHU.0b013e318214f30c","article-title":"Rituximab in the treatment of bullous systemic lupus erythematosus","volume":"17","author":"Alsanafi","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0315","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jaad.2014.02.036","article-title":"Anti-p200 pemphigoid","volume":"71","author":"Goletz","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0320","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2016.1099","article-title":"Laboratory diagnosis and clinical profile of anti-p200 pemphigoid","volume":"152","author":"Meijer","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0325","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bjd.14629","article-title":"Clinical and immunological features and outcome of anti-p200 pemphigoid","volume":"175","author":"Commin","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0330","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jdcr.2017.01.028","article-title":"Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab","volume":"3","author":"Rousseau","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0335","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0340","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3389\/fimmu.2018.01189","article-title":"Reversing autoimmunity combination of rituximab and intravenous immunoglobulin","volume":"9","author":"Ahmed","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0345","first-page":"1","article-title":"Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: a comprehensive survey of 71 consecutive patients from the initial use to 2007","volume":"5","author":"Peterson","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0350","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0360","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ijd.13140","article-title":"Literature-based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses","volume":"55","author":"Laniosz","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0370","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0375","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2008.02.001","article-title":"Management of viral hepatitis in hematologic malignancies","volume":"22","author":"Firpi","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0380","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/bjd.13355","article-title":"Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses","volume":"171","author":"Keith","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0385","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cncr.24742","article-title":"Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy","volume":"116","author":"Koo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0395","first-page":"41","article-title":"Risk of tuberculosis reactivation with rituximab therapy","volume":"11","author":"Alkadi","year":"2017","journal-title":"Int J Health Sci (Qassim)"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0400","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0405","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D34NS1K655","article-title":"A review of rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0415","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ced.13726","article-title":"Early-onset neutropenia after rituximab therapy for bullous pemphigoid","volume":"44","author":"Adler","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0420","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0425","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0430","doi-asserted-by":"crossref","unstructured":"Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra130.","DOI":"10.1126\/scitranslmed.3005166"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0435","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011:CD008794.","DOI":"10.1002\/14651858.CD008794"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0440","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0445","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0450","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0455","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0460","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198074","article-title":"Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis","volume":"13","author":"Agarwal","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0470","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0475","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0480","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","article-title":"Rituximab in refractory autoimmune bullous diseases","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0485","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0490","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/jdv.13330","article-title":"Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab","volume":"30","author":"Didona","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0495","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/ijd.13400","article-title":"Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey","volume":"55","author":"Uzun","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0500","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0505","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0510","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1111\/jdv.14144","article-title":"Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab","volume":"31","author":"Wei","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0515","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2009.11.588","article-title":"Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions","volume":"63","author":"Lehman","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0520","first-page":"182067","article-title":"Rituximab administration and reactivation of HBV","volume":"2010","author":"Tsutsumi","year":"2010","journal-title":"Hepat Res Treat"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0525","doi-asserted-by":"crossref","DOI":"10.1111\/aji.12601","article-title":"Management of pemphigus disease in pregnancy","volume":"77","author":"Tavakolpour","year":"2017","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0530","doi-asserted-by":"crossref","DOI":"10.1177\/1073274817729901","article-title":"Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review","volume":"24","author":"Bohra","year":"2017","journal-title":"Cancer Control"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0535","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0540","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2015.01.029","article-title":"Infectious complications in bullous pemphigoid: an analysis of risk factors","volume":"72","author":"Phoon","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0545","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1346-8138.12175","article-title":"Infection in autoimmune bullous diseases: a retrospective comparative study","volume":"40","author":"Lehman","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0550","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.det.2016.02.001","article-title":"Practice and educational gaps in blistering disease","volume":"34","author":"Ehsani-Chimeh","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0555","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1525-1470.2008.00751.x","article-title":"Severe bullous pemphigoid in an infant\u2014successful treatment with rituximab","volume":"25","author":"Schulze","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0560","first-page":"1200","article-title":"Is it time to re-evaluate the treatment of pemphigus?","volume":"11","author":"Leventhal","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0565","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2310\/7750.2014.14092","article-title":"Cost and resource use of pemphigus and pemphigoid disorders pre- and post-rituximab","volume":"19","author":"Heelan","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2019.07.023_bb0570","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X19301348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:15:24Z","timestamp":1760033724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X19301348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0738081X19301348"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.07.023","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2019.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}